Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 6 , Pages 489-491 , November 2009

Can we do better in developing new drugs for Alzheimer's disease?

  • Serge Gauthier

      Affiliations

    • Department of Psychiatry, Neurology & Neurosurgery, McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding author. Tel.: 514-766-2010; Fax: 514-888-4050.
    • ,
  • Philip Scheltens

      Affiliations

    • Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands

References 

  1. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale (GDS) for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136–1139
  2. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253–2262
  3. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The GuidAge study: methodological issues—a 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology. 2006;67:S6–S11
  4. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study in AD patients. Neurology. 2001;57:481–488
  5. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336:1216–1222
  6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746
  7. Petersen RC, Thomas RG, Grundman M, et al. Vitamin EW and donepezil for the treatment of Mild Cognitive Impairment. N Engl J Med. 2005;352:2379–2388
  8. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic of CSF markers of Alzheimer pathology in subjects with subjective cognitive impairment and mild cognitive impairment: the DESCRIPA Study. Lancet Neurol. 2009;8:619–627
  9. Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analysis of the MRI sub-group of the Alphase Study. J Nutr Health Aging. 2009;13:550–557
  10. Verwey NA, van der Flier WM, Blennow K, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem. 2009;46(Pt 3):235–240

PII: S1552-5260(09)02284-5

doi: 10.1016/j.jalz.2009.09.002

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 6 , Pages 489-491 , November 2009

Article Tools